search
Back to results

A Study of ICP-192 in Patients With FGFR2-Rearranged Unresectable or Metastatic Intrahepatic Cholangiocarcinoma

Primary Purpose

Intrahepatic Cholangiocarcinoma (ICC)

Status
Recruiting
Phase
Phase 2
Locations
China
Study Type
Interventional
Intervention
ICP-192
Sponsored by
Beijing InnoCare Pharma Tech Co., Ltd.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Intrahepatic Cholangiocarcinoma (ICC)

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Signed the ICF and Age ≥ 18 years old, either sex. ECOG score of 0-1. Life expectancy > 3 months. Histopathologically or cytopathologically confirmed intrahepatic cholangiocarcinoma with unresectable, recurrent or metastatic (AJCC 2017, 8th edition, TNM stage IV) tumor that has progressed following at least one line of systemic chemotherapy and progression/recurrence within 6 months after neoadjuvant/adjuvant chemotherapy may be included. FGFR2 fusion /rearrangement as confirmed by the central laboratory. At least one measurable lesion at screening as target lesion per RECIST 1.1. Organ functions meeting the protocol requirements. Contraception according to the protocol requirements. Exclusion Criteria: Presence of other malignancies requiring medical intervention. Prior treatment with selective FGFR inhibitors or FGFR antibodies. Treatment with biological products, radical radiotherapy, and other investigational drugs within 4 weeks prior to the first dose of study drug. Chemotherapy within 3 weeks prior to the first dose of study drug. Known symptomatic central nervous system (CNS) metastases. Patients who have not recovered from the toxicity caused by previous anti-tumor treatment and have ≥ Grade 2 adverse events (judged per CTCAE V5.0 evaluation criterion) at the first dose of study drug. Currently uncontrolled cardiovascular and cerebrovascular diseases, or a past medical history. Any unstable or uncontrolled systemic disease as judged by the investigator, such as: active infection requiring intravenous therapy, uncontrolled hypertension (After treatment systolic blood pressure ≥ 150 mmHg and/or diastolic blood pressure ≥ 90 mmHg), and diabetes mellitus (HbA1c > 8%). Current active bleeding, such as deep venous thrombosis, portal hypertension signs leading to gastroesophageal venous bleeding. Wound with active infection. Major surgical procedures within 4 weeks prior to the first dose of the study drug or minor surgical procedures within 2 weeks prior to the first dose of the study drug. Any corneal or retinal abnormalities that may result in an increased risk of ocular toxicity History and/or current evidence of extensive tissue calcification, including but not limited to calcification in soft tissues, kidney, intestine, myocardium, vasculature and/or the lungs, with the exception of lymph node calcification, mild pulmonary parenchymal calcification, and asymptomatic coronary artery calcification. Clinically serious gastrointestinal dysfunction that may affect the intake, transport or absorption of the study drug (such as poorly controlled nausea, vomiting, diarrhea; malabsorption syndrome; intestinal obstruction and small bowel resection, etc.), or the patient was unable to swallow the drug orally. Active HBV infection, Active HCV infection, HIV infection. Female subjects who are pregnant or breastfeeding, or plan to have a pregnancy within 6 months after the last dose of the study drug; or male subjects who plan to father a child during the study or within 6 months after the last dose of the study drug. The last dose of strong CYP3A inhibitor or CYP3A inducer (including food, western medicine, traditional Chinese medicine) is less than 5 half-lives before the first dose of study drug, or plans to take concomitant drugs or foods with strong CYP3A inhibition or induction during the study. Known allergy to any excipients of the study drug. Subjects with conditions that in the investigator's opinion are not suitable for participating in this trial.

Sites / Locations

  • Anhui Provincial Hospital
  • Cancer Hospital, Chinese Academy of Medical Sciences
  • Peking Union Medical College Hospital
  • Beijing Youan Hosptital,Capital Medical University
  • Beijing Cancer Hospital
  • Beijing HospitalRecruiting
  • Fujian Cancer Hospital
  • Fujian Medical University Union Hospital
  • Mengchao hepatobiliary Hospital of FuJian Medical university
  • Foshan First People's Hospital
  • Sun Yat-sen Memorial Hospital
  • Sun Yat-sen University Cancer Center
  • ZhuJiang Hospital of Southern Medical UniversityRecruiting
  • Hebei Medical University Fourth Hospital
  • Harbin Medical University Cancer Hospital
  • Henan Cancer Hospital
  • First Affiliated Hospital of Zhengzhou University.
  • Zhongnan Hospital of Wuhan University
  • Hubei Cancer Hospital
  • Human Provincial People's Hospital
  • Hunan Cancer HospitalRecruiting
  • The Third Xiangya Hospital of Central South Uninversity
  • Changzhou Tumor Hospital
  • Jiangyin Renmin Hospital
  • The Affiliated Hospital of Nanjing University Meidical School
  • The Second Affiliated Hospital of Soochow University
  • Xuzhou Central Hospital
  • The Second Affiliated Hospital of Nanchang University
  • Shengjing Hospital of China Medical University
  • Liaoning Cancer Hospital&Institute
  • Jiangxi Cancer Hospital
  • General Hospital of Ningxia Medical University
  • Tangdu Hospital of the Fourth Military Medical University
  • Qilu HospitalRecruiting
  • Jinan Central HospitalRecruiting
  • Affiliated Cancer Hospital of Shandong First Medical University
  • ZhongShan Hospital
  • The Third Affiliated Hospital of Naval Medical University
  • Sichuan Cancer Hospital
  • West China Hospital of Sichuan University
  • Tianjin Cancer Hospital
  • Zhejiang Cancer Hospital
  • Shulan(Hangzhou) Hospital
  • The First Affiliated Hospital of Zhejiang University School of Medicine

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

ICP-192

Arm Description

Outcomes

Primary Outcome Measures

Objective response rate (ORR)

Secondary Outcome Measures

Progression-free survival (PFS)
Disease control rate (DCR)
Duration of response (DOR)
Time to response (TTR)
Overall survival (OS)
The adverse event (AE) of ICP-192 assessed by NCI-CTCAE V5.0
Maximum concentration (Cmax)
Time to maximum concentration (Tmax)
Half-life (T1/2)
Area under the concentration-time curve (AUC)
Apparent clearance (CL/F)
Terminal apparent volume of distribution (Vz/F)

Full Information

First Posted
December 23, 2022
Last Updated
December 23, 2022
Sponsor
Beijing InnoCare Pharma Tech Co., Ltd.
search

1. Study Identification

Unique Protocol Identification Number
NCT05678270
Brief Title
A Study of ICP-192 in Patients With FGFR2-Rearranged Unresectable or Metastatic Intrahepatic Cholangiocarcinoma
Official Title
A Single-Arm, Open-Label, Multicenter Phase II Study to Evaluate the Efficacy and Safety of ICP-192 in Subjects With Unresectable or Metastatic Intrahepatic Cholangiocarcinoma With FGFR2 Fusions/Rearrangements Who Have Failed Prior Therapy.
Study Type
Interventional

2. Study Status

Record Verification Date
November 2022
Overall Recruitment Status
Recruiting
Study Start Date
November 15, 2022 (Actual)
Primary Completion Date
May 2026 (Anticipated)
Study Completion Date
December 2026 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Beijing InnoCare Pharma Tech Co., Ltd.

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No

5. Study Description

Brief Summary
This is a single-arm, open-label, multi-center phase 2 clinical trial of ICP-192. The purpose of this study is to evaluate the efficacy and safety in patients with FGFR2-Rearranged unresectable or metastatic intrahepatic cholangiocarcinoma who failed prior therapy

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Intrahepatic Cholangiocarcinoma (ICC)

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
64 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
ICP-192
Arm Type
Experimental
Intervention Type
Drug
Intervention Name(s)
ICP-192
Intervention Description
ICP-192 is a round, uncoated tablet, 5mg, orally.
Primary Outcome Measure Information:
Title
Objective response rate (ORR)
Time Frame
Up to 3 years
Secondary Outcome Measure Information:
Title
Progression-free survival (PFS)
Time Frame
Up to 3 years
Title
Disease control rate (DCR)
Time Frame
Up to 3 years
Title
Duration of response (DOR)
Time Frame
Up to 3 years
Title
Time to response (TTR)
Time Frame
Up to 3 years
Title
Overall survival (OS)
Time Frame
Up to 3 years
Title
The adverse event (AE) of ICP-192 assessed by NCI-CTCAE V5.0
Time Frame
Up to 3 years
Title
Maximum concentration (Cmax)
Time Frame
Up to 3 years
Title
Time to maximum concentration (Tmax)
Time Frame
Up to 3 years
Title
Half-life (T1/2)
Time Frame
Up to 3 years
Title
Area under the concentration-time curve (AUC)
Time Frame
Up to 3 years
Title
Apparent clearance (CL/F)
Time Frame
Up to 3 years
Title
Terminal apparent volume of distribution (Vz/F)
Time Frame
Up to 3 years
Other Pre-specified Outcome Measures:
Title
To explore the relationship between blood phosphorus and clinical efficacy
Time Frame
Up to 3 years

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Signed the ICF and Age ≥ 18 years old, either sex. ECOG score of 0-1. Life expectancy > 3 months. Histopathologically or cytopathologically confirmed intrahepatic cholangiocarcinoma with unresectable, recurrent or metastatic (AJCC 2017, 8th edition, TNM stage IV) tumor that has progressed following at least one line of systemic chemotherapy and progression/recurrence within 6 months after neoadjuvant/adjuvant chemotherapy may be included. FGFR2 fusion /rearrangement as confirmed by the central laboratory. At least one measurable lesion at screening as target lesion per RECIST 1.1. Organ functions meeting the protocol requirements. Contraception according to the protocol requirements. Exclusion Criteria: Presence of other malignancies requiring medical intervention. Prior treatment with selective FGFR inhibitors or FGFR antibodies. Treatment with biological products, radical radiotherapy, and other investigational drugs within 4 weeks prior to the first dose of study drug. Chemotherapy within 3 weeks prior to the first dose of study drug. Known symptomatic central nervous system (CNS) metastases. Patients who have not recovered from the toxicity caused by previous anti-tumor treatment and have ≥ Grade 2 adverse events (judged per CTCAE V5.0 evaluation criterion) at the first dose of study drug. Currently uncontrolled cardiovascular and cerebrovascular diseases, or a past medical history. Any unstable or uncontrolled systemic disease as judged by the investigator, such as: active infection requiring intravenous therapy, uncontrolled hypertension (After treatment systolic blood pressure ≥ 150 mmHg and/or diastolic blood pressure ≥ 90 mmHg), and diabetes mellitus (HbA1c > 8%). Current active bleeding, such as deep venous thrombosis, portal hypertension signs leading to gastroesophageal venous bleeding. Wound with active infection. Major surgical procedures within 4 weeks prior to the first dose of the study drug or minor surgical procedures within 2 weeks prior to the first dose of the study drug. Any corneal or retinal abnormalities that may result in an increased risk of ocular toxicity History and/or current evidence of extensive tissue calcification, including but not limited to calcification in soft tissues, kidney, intestine, myocardium, vasculature and/or the lungs, with the exception of lymph node calcification, mild pulmonary parenchymal calcification, and asymptomatic coronary artery calcification. Clinically serious gastrointestinal dysfunction that may affect the intake, transport or absorption of the study drug (such as poorly controlled nausea, vomiting, diarrhea; malabsorption syndrome; intestinal obstruction and small bowel resection, etc.), or the patient was unable to swallow the drug orally. Active HBV infection, Active HCV infection, HIV infection. Female subjects who are pregnant or breastfeeding, or plan to have a pregnancy within 6 months after the last dose of the study drug; or male subjects who plan to father a child during the study or within 6 months after the last dose of the study drug. The last dose of strong CYP3A inhibitor or CYP3A inducer (including food, western medicine, traditional Chinese medicine) is less than 5 half-lives before the first dose of study drug, or plans to take concomitant drugs or foods with strong CYP3A inhibition or induction during the study. Known allergy to any excipients of the study drug. Subjects with conditions that in the investigator's opinion are not suitable for participating in this trial.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Jin Li
Phone
021-38804518
Email
lijin@csco.org.cn
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Jin Li
Organizational Affiliation
Shanghai East Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
Anhui Provincial Hospital
City
Hefei
State/Province
Anhui
ZIP/Postal Code
230036
Country
China
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Lianxin Liu
Email
liulx@ustc.edu.cn
Facility Name
Cancer Hospital, Chinese Academy of Medical Sciences
City
Beijing
State/Province
Beijing
ZIP/Postal Code
100021
Country
China
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Xiao Li
Email
simonlixiao@263.net
Facility Name
Peking Union Medical College Hospital
City
Beijing
State/Province
Beijing
ZIP/Postal Code
100032
Country
China
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Haitao Zhao
Email
zhaoht@pumch.cn
Facility Name
Beijing Youan Hosptital,Capital Medical University
City
Beijing
State/Province
Beijing
ZIP/Postal Code
100069
Country
China
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Chunwang Yuan
Email
18612778605@163.com
First Name & Middle Initial & Last Name & Degree
Hongyong Zhang
Email
13810108505@163.com
Facility Name
Beijing Cancer Hospital
City
Beijing
State/Province
Beijing
ZIP/Postal Code
100142
Country
China
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Xu Zhu
Email
drzhuxu@163.com
Facility Name
Beijing Hospital
City
Beijing
State/Province
Beijing
ZIP/Postal Code
100730
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Yunbo Zhao
Email
zhaoyb1206@163.com
Facility Name
Fujian Cancer Hospital
City
Fujian
State/Province
Fujian
ZIP/Postal Code
350011
Country
China
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Hailan Lin
Email
fjzljr@qq.com
Facility Name
Fujian Medical University Union Hospital
City
Fuzhou
State/Province
Fujian
ZIP/Postal Code
350001
Country
China
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Yanling Chen
Email
drchenyl@126.com
Facility Name
Mengchao hepatobiliary Hospital of FuJian Medical university
City
FuZhou
State/Province
Fujian
ZIP/Postal Code
350025
Country
China
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Kecan Lin
Email
kclin2002@126.com
Facility Name
Foshan First People's Hospital
City
Foshan
State/Province
Guangdong
ZIP/Postal Code
528000
Country
China
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jing Wu
Email
13877296262@163.com
Facility Name
Sun Yat-sen Memorial Hospital
City
Guangzhou
State/Province
Guangdong
ZIP/Postal Code
510000
Country
China
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Chao Liu
Email
liuchao3@mail.sysu.edu.cn
Facility Name
Sun Yat-sen University Cancer Center
City
Guangzhou
State/Province
Guangdong
ZIP/Postal Code
510060
Country
China
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Ruihua Xu
Email
xurh@sysucc.org.cn
Facility Name
ZhuJiang Hospital of Southern Medical University
City
Guangzhou
State/Province
Guangdong
ZIP/Postal Code
510280
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Weiming Ding
Email
DWM-2001@163.com
Facility Name
Hebei Medical University Fourth Hospital
City
Shijiazhuang
State/Province
Hebei
ZIP/Postal Code
050011
Country
China
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Fei Yin
Email
Yinfei_4y@sina.com
Facility Name
Harbin Medical University Cancer Hospital
City
Harbin
State/Province
Heilongjiang
ZIP/Postal Code
150081
Country
China
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Zhiwei Li
Email
lzhw0451@163.com
Facility Name
Henan Cancer Hospital
City
Zhengzhou
State/Province
Henan
ZIP/Postal Code
450003
Country
China
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Xinfang Hou
Email
houxinfang2013@163.com
Facility Name
First Affiliated Hospital of Zhengzhou University.
City
Zhengzhou
State/Province
Henan
ZIP/Postal Code
450066
Country
China
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Qingxia Fan
Email
fqx2243@126.com
Facility Name
Zhongnan Hospital of Wuhan University
City
Wuhan
State/Province
Hubei
ZIP/Postal Code
430062
Country
China
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Fuxiang Zhou
Email
happyzhoufx@sina.com
Facility Name
Hubei Cancer Hospital
City
Wuhan
State/Province
Hubei
ZIP/Postal Code
430079
Country
China
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Zhang Feng
Email
zhangfeng_329@126.com
Facility Name
Human Provincial People's Hospital
City
Changsha
State/Province
Hunan
ZIP/Postal Code
410002
Country
China
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Chuang Peng
Email
1518364280@qq.com
Facility Name
Hunan Cancer Hospital
City
Changsha
State/Province
Hunan
ZIP/Postal Code
410013
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Shanzhi Gu
Email
105575191@qq.com
Facility Name
The Third Xiangya Hospital of Central South Uninversity
City
Changsha
State/Province
Hunan
ZIP/Postal Code
410013
Country
China
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Feizhou Huang
Email
Huangfeizhou1009@163.com
Facility Name
Changzhou Tumor Hospital
City
Changzhou
State/Province
Jiangsu
ZIP/Postal Code
213000
Country
China
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Bi Yanzhi
Email
623447244@qq.com
Facility Name
Jiangyin Renmin Hospital
City
Jiangyin
State/Province
Jiangsu
ZIP/Postal Code
214499
Country
China
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Lichun Deng
Email
18921233265@163.com
Facility Name
The Affiliated Hospital of Nanjing University Meidical School
City
Nanjing
State/Province
Jiangsu
ZIP/Postal Code
210000
Country
China
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Shen Jie
Email
shenjie2008nju@163.com
Facility Name
The Second Affiliated Hospital of Soochow University
City
Suzhou
State/Province
Jiangsu
ZIP/Postal Code
215004
Country
China
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Zhixiang Zhuang
Email
13951106391@139.com
Facility Name
Xuzhou Central Hospital
City
Xuzhou
State/Province
Jiangsu
ZIP/Postal Code
221009
Country
China
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jinsong Li
Email
18952171970@189.cn
Facility Name
The Second Affiliated Hospital of Nanchang University
City
Nanchang
State/Province
Jiangxi
ZIP/Postal Code
330000
Country
China
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jianbing Wu
Email
hhgwjb@163.com
Facility Name
Shengjing Hospital of China Medical University
City
Shenyang
State/Province
Liaoning
ZIP/Postal Code
110004
Country
China
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Chaoliu Dai
Email
278170678@qq.com
Facility Name
Liaoning Cancer Hospital&Institute
City
Shenyang
State/Province
Liaoning
ZIP/Postal Code
110042
Country
China
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jingdong Zhang
Email
13804027878@163.com
Facility Name
Jiangxi Cancer Hospital
City
Nanchang
State/Province
Nanchang
ZIP/Postal Code
330029
Country
China
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Qiang Tu
Email
52689703@qq.com
Facility Name
General Hospital of Ningxia Medical University
City
Yinchuan
State/Province
Ningxia
ZIP/Postal Code
750004
Country
China
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Ping Chen
Email
Chenping2536@qq.com
Facility Name
Tangdu Hospital of the Fourth Military Medical University
City
Xi'an
State/Province
Shaanxi
ZIP/Postal Code
710038
Country
China
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jikai Yin
Email
yjkfmmuu@hotmail.com
Facility Name
Qilu Hospital
City
Jinan
State/Province
Shandong
ZIP/Postal Code
250012
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Yufeng Cheng
Email
qlcyf@163.com
Facility Name
Jinan Central Hospital
City
Jinan
State/Province
Shandong
ZIP/Postal Code
250013
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
MeiLi Sun
Email
s18953116532@163.com
Facility Name
Affiliated Cancer Hospital of Shandong First Medical University
City
Jinan
State/Province
Shandong
ZIP/Postal Code
250117
Country
China
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
ZuoXing Niu
Email
nzxsdth@163.com
First Name & Middle Initial & Last Name & Degree
Tian He
Email
tianhejn@sina.com
Facility Name
ZhongShan Hospital
City
Shanghai
State/Province
Shanghai
ZIP/Postal Code
200123
Country
China
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Zhou Jian
Email
zhou.jian@zs-hospital.sh.cn
Facility Name
The Third Affiliated Hospital of Naval Medical University
City
Shanghai
State/Province
Shanghai
ZIP/Postal Code
200433
Country
China
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Kui Wang
Email
wangkuiykl@163.com
Facility Name
Sichuan Cancer Hospital
City
Chengdu
State/Province
Sichuan
ZIP/Postal Code
610041
Country
China
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Xielin Feng
Email
llxxff17@163.com
Facility Name
West China Hospital of Sichuan University
City
Chengdu
State/Province
Sichuan
ZIP/Postal Code
610041
Country
China
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Lunan Yan
Email
yanlunan688@163.com
Facility Name
Tianjin Cancer Hospital
City
Tianjin
State/Province
Tianjin
ZIP/Postal Code
300060
Country
China
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Wei Lu
Email
luwei1966@126.com
Facility Name
Zhejiang Cancer Hospital
City
Hangzhou
State/Province
Zhejiang
ZIP/Postal Code
310005
Country
China
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jieer Ying
Email
jieerying01@163.com
Facility Name
Shulan(Hangzhou) Hospital
City
Hangzhou
State/Province
Zhejiang
ZIP/Postal Code
310009
Country
China
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Wu zhang
Email
Wu.zhang@shulan.com
Facility Name
The First Affiliated Hospital of Zhejiang University School of Medicine
City
Hangzhou
State/Province
Zhejiang
ZIP/Postal Code
310009
Country
China
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Tingbo Liang
Email
liangtingbo@zju.edu.cn

12. IPD Sharing Statement

Learn more about this trial

A Study of ICP-192 in Patients With FGFR2-Rearranged Unresectable or Metastatic Intrahepatic Cholangiocarcinoma

We'll reach out to this number within 24 hrs